On Nov. 11, 2021, Roche announced that the European Medicines Agencyﾒs (EMA) Committee for Medicinal Products for Human Use had recommended the approval of the antibody combination, Ronapreveﾙ (casirivimab and imdevimab), for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of their disease becoming severe, and for preventing COVID-19 in people aged 12 years and older weighing at least 40 kilograms (pre- or post-exposure prophylaxis).